Bioxytran, Inc. (BIXT)
USD 0.09
(-0.89%)
USD 0.09
(-0.89%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.82 Million USD | -79.0% |
| 2022 | -2.13 Million USD | 49.36% |
| 2021 | -4.21 Million USD | -232.18% |
| 2020 | -1.26 Million USD | 22.24% |
| 2019 | -1.63 Million USD | -658.01% |
| 2018 | - USD | 26.56% |
| 2017 | -310.58 Thousand USD | 54.47% |
| 2016 | -661.32 Thousand USD | 68.41% |
| 2015 | -2.03 Million USD | -66.67% |
| 2014 | -1.28 Million USD | 36.37% |
| 2013 | -1.71 Million USD | 14.57% |
| 2012 | -2.24 Million USD | 3.2% |
| 2011 | -4.39 Million USD | -615.55% |
| 2010 | -324.69 Thousand USD | -19.31% |
| 2009 | -271.23 Thousand USD | -1023.89% |
| 2008 | -24.21 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -783.79 Thousand USD | 23.66% |
| 2024 Q3 | -346.2 Thousand USD | 43.19% |
| 2024 Q2 | -609.38 Thousand USD | 22.25% |
| 2023 Q2 | -1.02 Million USD | -36.18% |
| 2023 Q3 | 50.5 Thousand USD | 104.94% |
| 2023 Q4 | -1.02 Million USD | -2133.03% |
| 2023 FY | - USD | -79.0% |
| 2023 Q1 | -750.24 Thousand USD | 5.27% |
| 2022 Q2 | -537.22 Thousand USD | 34.41% |
| 2022 Q1 | -819.1 Thousand USD | 12.49% |
| 2022 FY | - USD | 49.36% |
| 2022 Q4 | -792 Thousand USD | -5667.72% |
| 2022 Q3 | 14.22 Thousand USD | 102.65% |
| 2021 Q1 | -1.68 Million USD | -117.56% |
| 2021 Q3 | -547.24 Thousand USD | 47.5% |
| 2021 FY | - USD | -232.18% |
| 2021 Q4 | -935.96 Thousand USD | -71.03% |
| 2021 Q2 | -1.04 Million USD | 38.28% |
| 2020 Q3 | -114.44 Thousand USD | -2.27% |
| 2020 FY | - USD | 22.24% |
| 2020 Q2 | -111.9 Thousand USD | 57.94% |
| 2020 Q1 | -266.04 Thousand USD | 46.76% |
| 2020 Q4 | -776.3 Thousand USD | -578.3% |
| 2019 FY | - USD | -658.01% |
| 2019 Q4 | -499.66 Thousand USD | 41.24% |
| 2019 Q2 | -106.49 Thousand USD | 17.84% |
| 2019 Q1 | -129.62 Thousand USD | 45.8% |
| 2019 Q3 | -850.31 Thousand USD | -698.44% |
| 2018 Q2 | -108.3 Thousand USD | -364.84% |
| 2018 Q4 | -239.17 Thousand USD | -403.27% |
| 2018 FY | - USD | 26.56% |
| 2018 Q1 | -23.3 Thousand USD | -1679.98% |
| 2018 Q3 | -47.52 Thousand USD | 56.12% |
| 2017 Q3 | 55.21 Thousand USD | 121.73% |
| 2017 FY | - USD | 54.47% |
| 2017 Q1 | -58.27 Thousand USD | -141.13% |
| 2017 Q4 | -1309.00 USD | -102.37% |
| 2017 Q2 | -254.03 Thousand USD | -335.94% |
| 2016 FY | - USD | 68.41% |
| 2016 Q4 | 141.69 Thousand USD | 168.34% |
| 2016 Q1 | -441.49 Thousand USD | -333.82% |
| 2016 Q3 | -207.35 Thousand USD | -51.91% |
| 2016 Q2 | -136.49 Thousand USD | 69.08% |
| 2015 FY | - USD | -66.67% |
| 2015 Q1 | -22.66 Thousand USD | 85.96% |
| 2015 Q2 | -1.89 Million USD | -8281.93% |
| 2015 Q3 | -13.6 Thousand USD | 99.28% |
| 2015 Q4 | -101.76 Thousand USD | -647.97% |
| 2014 Q2 | -41.61 Thousand USD | -151.82% |
| 2014 Q3 | -1.09 Million USD | -2542.97% |
| 2014 FY | - USD | 36.37% |
| 2014 Q4 | -161.43 Thousand USD | 85.32% |
| 2014 Q1 | 80.3 Thousand USD | 203.58% |
| 2013 Q4 | -77.53 Thousand USD | 69.25% |
| 2013 FY | - USD | 14.57% |
| 2013 Q1 | -952.59 Thousand USD | -45.43% |
| 2013 Q2 | -618.84 Thousand USD | 35.04% |
| 2013 Q3 | -252.09 Thousand USD | 59.26% |
| 2012 Q1 | -32.27 Thousand USD | 97.43% |
| 2012 Q2 | -181.44 Thousand USD | -462.22% |
| 2012 Q4 | -655 Thousand USD | -37.57% |
| 2012 Q3 | -476.12 Thousand USD | -162.41% |
| 2012 FY | - USD | 3.2% |
| 2011 Q4 | -1.25 Million USD | -473.61% |
| 2011 FY | - USD | -615.55% |
| 2011 Q2 | -132.18 Thousand USD | 81.6% |
| 2011 Q1 | -718.24 Thousand USD | -1084.09% |
| 2011 Q3 | -218.65 Thousand USD | -65.42% |
| 2010 Q4 | -60.65 Thousand USD | 13.07% |
| 2010 FY | - USD | -19.31% |
| 2010 Q2 | -120.51 Thousand USD | -62.34% |
| 2010 Q1 | -74.23 Thousand USD | 46.31% |
| 2010 Q3 | -69.77 Thousand USD | 42.1% |
| 2009 Q4 | -138.27 Thousand USD | -62.41% |
| 2009 Q3 | -85.14 Thousand USD | -134.04% |
| 2009 Q1 | -12.87 Thousand USD | 0.0% |
| 2009 Q2 | -36.37 Thousand USD | -182.6% |
| 2009 FY | - USD | -1023.89% |
| 2008 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 94.622% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 35.567% |
| SQZ Biotechnologies Company | -64.14 Million USD | 94.044% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 78.007% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 104.062% |
| Mesoblast Limited | -62.38 Million USD | 93.877% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -148.7% |
| Genus plc | 73.7 Million USD | 105.183% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 42.22% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -7.701% |
| Marizyme, Inc. | -34.28 Million USD | 88.857% |
| ContraFect Corporation | -64.99 Million USD | 94.123% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 56.451% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 15.599% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -172.516% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -44.459% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -64.391% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -637.415% |
| Accustem Sciences Inc. | -3.74 Million USD | -1.968% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 92.079% |
| EV Biologics, Inc. | -1.26 Million USD | -201.48% |
| Q BioMed Inc. | -617.62 Thousand USD | -518.519% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 206.947% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -504.066% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -67.221% |
| Biomind Labs Inc. | -1.03 Million USD | -269.257% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 138.677% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 46.655% |
| Skye Bioscience, Inc. | -13.54 Million USD | 71.802% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -156.832% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -15180.588% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 1.652% |
| IMV Inc. | -35.52 Million USD | 89.246% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 75.928% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -52.686% |
| GB Sciences, Inc. | -1.41 Million USD | -169.046% |
| Alpha Cognition Inc. | -9.7 Million USD | 60.64% |
| HST Global, Inc. | -5303.00 USD | -71937.469% |
| CSL Limited | 4.78 Billion USD | 100.08% |
| Halberd Corporation | -74.27 Thousand USD | -5042.97% |
| Enzolytics Inc. | -2.12 Million USD | -80.023% |
| Resverlogix Corp. | -11.74 Million USD | 67.466% |
| Affymax, Inc. | -14.29 Million USD | 73.276% |
| SYBLEU INC | -141.57 Thousand USD | -2598.397% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -24.718% |
| argenx SE | -216.02 Million USD | 98.232% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 93.097% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 413.899% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -154.862% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 1108.369% |
| AVAX Technologies, Inc. | -6.11 Million USD | 37.504% |
| Zenith Capital Corp. | -8.6 Million USD | 55.611% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.464% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -21828.403% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -56.15% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -2070.238% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 90.362% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -32.079% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -265.106% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 56913.608% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -118.294% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -98.872% |
| BioStem Technologies, Inc. | -7.55 Million USD | 49.426% |
| ONE Bio Corp. | 13.61 Million USD | 128.062% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -2009.553% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -85.714% |
| Agentix Corp. | -1.37 Million USD | -178.486% |
| LadRx Corporation | 412.28 Thousand USD | 1026.584% |
| Cell Source, Inc. | -4.27 Million USD | 10.588% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -940.286% |
| Regen BioPharma, Inc. | 1.46 Million USD | 360.591% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -307.722% |
| NovAccess Global Inc. | -1.03 Million USD | -269.169% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 143.147% |
| Itoco Inc. | -1.86 Million USD | -104.396% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -906.308% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -242.307% |
| Kadimastem Ltd | -2.62 Million USD | -45.564% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1497.385% |
| CytoDyn Inc. | -18.02 Million USD | 78.811% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -4733.855% |
| Mobile Lads Corp. | -2.24 Million USD | -70.454% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -31138.425% |
| Qrons Inc. | -40.08 Thousand USD | -9431.067% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -686.56% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 824.29% |
| Rebus Holdings, Inc. | -951 Thousand USD | -301.698% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -259.709% |
| International Stem Cell Corporation | 202 Thousand USD | 1991.162% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -7157.118% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -55.169% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 89.35% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -8389.216% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -39.523% |
| Neutra Corp. | -181.24 Thousand USD | -2007.702% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 81.05% |
| PureTech Health plc | -11.62 Million USD | 67.144% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 81.049% |
| IXICO plc | -707 Thousand USD | -440.332% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 50.291% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 92.098% |
| CSL Limited | 4.73 Billion USD | 100.081% |
| Cellectis S.A. | -92.63 Million USD | 95.876% |